At a glance
ClinicalIndex Comparison RecordN/ACompleted· 220 enrolled
Drug / intervention
Glibenclamide Tablets +1 moredrug
Likely dose
Glibenclamide Tablets 1.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): a Multi-center Randomized, Controlled, Assessor-blinded Trial
In Brief
A clinical study evaluating Glibenclamide Tablets and Standard management for ICH for Intracerebral Hemorrhage. Completed, enrolled 220 participants across 5 sites.
Detailed Summary
The purpose of the present study is to explore the efficacy of small doses of oral glibenclamide on brain edema after acute primary intracerebral hemorrhage (ICH), and improving the prognosis of patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracerebral Hemorrhage
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2018
Primary CompletionSep 2020
TodayJul 2026
First PostedNov 15, 2018
Enrollment StartDec 15, 2018
Primary CompletionSep 23, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.6 years ago
Interventions
Glibenclamide Tabletsdrug
Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
Standard management for ICHother
Usual care and drug in hospital